Industry-Leading Lentiviral Titers Through Our Optimized VirusExpress® Production Technology

Along with its many notable advantages, lentiviral vectors' attractiveness lies in their ability to be used in a wide range of cell and gene therapy indications, beyond rare diseases to serve larger patient populations. Recent regulatory approvals and clinical trial successes have led to a growing pipeline and interest in therapies using lentiviral vectors. And with that, an increased need for a robust scalable production technology that improves overall yield and quality.

In this webinar, upstream and downstream innovation scientists from MilliporeSigma will explore how they optimized their VirusExpress^® production technology for lentiviral vectors to maximize titer while providing a streamlined platform to accelerate development timelines to clinical trials.